Functional characterization of a chronic cyclophosphamide-induced overactive bladder model in mice

Neurourology and Urodynamics

Volumn 30, Issue 8, 2011, Pages 1659-1665

  Boudes, Mathieu ^a,b   Uvin, Pieter ^a,b   Kerselaers, Sara ^a   Vennekens, Rudi ^a   Voets, Thomas ^a   De Ridder, Dirk ^b  

^a LABORATORY OF MOLECULAR AND CELLULAR SIGNALING   (Belgium)

^b SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

Author keywords

animal model; chronic cystitis; cyclophosphamide; mice; overactive bladder

Indexed keywords

CYCLOPHOSPHAMIDE; EOSIN; HEMATOXYLIN; NERVE GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; C57BL 6 MOUSE; CHRONIC DISEASE; CONTROLLED STUDY; CYSTITIS; CYSTOMETRY; DETRUSOR MUSCLE; DISEASE ASSOCIATION; DOSE RESPONSE; HEART RATE; HYPERALGESIA; HYPERPLASIA; MALE; MICTURITION; MOUSE; MUSCLE CONTRACTION; NONHUMAN; OVERACTIVE BLADDER; PAIN; PATHOPHYSIOLOGY; SENSITIVITY ANALYSIS; SPOTTING; STAINING; TELEMETRY; URODYNAMICS;

ABDOMINAL PAIN; ANIMALS; BODY TEMPERATURE; BODY WEIGHT; CYCLOPHOSPHAMIDE; CYSTITIS, INTERSTITIAL; DISEASE MODELS, ANIMAL; HEART RATE; HYPERALGESIA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NERVE GROWTH FACTOR; PRESSURE; TIME FACTORS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 80054812686     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.21180     Document Type: Article

References (38)

1. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-6.
2. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-14 discussion 1314-1305.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
4. Schurch B, Schmid DM, Stohrer M,. Treatment of neurogenic incontinence with botulinum toxin A. N Engl J Med 2000; 342: 665.
5. Andersson KE, Chapple CR, Cardozo L, et al. Pharmacological treatment of overactive bladder: Report from the International Consultation on Incontinence. Curr Opin Urol 2009; 19: 380-94.
6. Cox PJ,. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 2045-9.
7. Reynolds RD, Simerville JJ, O'Hara DD, et al. Hemorrhagic cystitis due to cyclophosphamide. J Urol 1969; 101: 45-7.
8. De Ridder D, van Poppel H, Demonty L, et al. Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. J Urol 1998; 159: 1881-4.
9. Everaerts W, Zhen X, Ghosh D, et al. Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc Natl Acad Sci USA 2010; 107: 19084-9.
10. Masuda H, Ichiyanagi N, Yokoyama M, et al. Muscarinic receptor activation in the lumbosacral spinal cord ameliorates bladder irritation in rat cystitis models. BJU Int 2009; 104: 1531-7.
11. Juszczak K, Krolczyk G, Filipek M, et al. Animal models of overactive bladder: Cyclophosphamide (CYP)-induced cystitis in rats. Folia Med Cracov 2007; 48: 113-23.
12. Boucher M, Meen M, Codron JP, et al. Cyclophosphamide-induced cystitis in freely-moving conscious rats: Behavioral approach to a new model of visceral pain. J Urol 2000; 164: 203-8.
13. Bon K, Lichtensteiger CA, Wilson SG, et al. Characterization of cyclophosphamide cystitis, a model of visceral and referred pain, in the mouse: Species and strain differences. J Urol 2003; 170: 1008-12.
14. Vizzard MA, Erdman SL, de Groat WC,. Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation. J Comp Neurol 1996; 370: 191-202.
15. Vera PL, Iczkowski KA, Wang X, et al. Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association. PLoS One 2008a; 3: e3898.
16. Vera PL, Wang X, Meyer-Siegler KL,. Upregulation of macrophage migration inhibitory factor (MIF) and CD74, receptor for MIF, in rat bladder during persistent cyclophosphamide-induced inflammation. Exp Biol Med (Maywood) 2008b; 233: 620-6.
17. Mills PA, Huetteman DA, Brockway BP, Zwiers LM, Gelsema AJ, Schwartz RS, Kramer K,. A new method for measurement of blood pressure, heart rate, and activity in the mouse by radiotelemetry. J Appl Physiol. 2000; 88: 1537-1544.
18. Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63.
19. Dixon WJ,. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20: 441-62.
20. Gevaert T, Vriens J, Segal A, et al. Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 2007; 117: 3453-62.
21. Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: Results from the EPIC study. BJU Int 2008; 101: 1388-95.
22. Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006; 50: 1050-7.
23. Gulur DM, Drake MJ,. Management of overactive bladder. Nat Rev Urol 2010; 7: 572-82.
24. Garnett S, Swithinbank L, Ellis-Jones J, et al. The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int 2009; 104: 948-53.
25. Apostolidis A, Jacques TS, Freeman A, et al. Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity. Eur Urol 2008; 53: 1245-53.
26. de Groat WC,. The urothelium in overactive bladder: Passive bystander or active participant? Urology 2004; 64: 7-11.
27. Greka A, Navarro B, Oancea E, et al. TRPC5 is a regulator of hippocampal neurite length and growth cone morphology. Nat Neurosci 2003; 6: 837-45.
28. Hu VY, Malley S, Dattilio A, et al. COX-2 and prostanoid expression in micturition pathways after cyclophosphamide-induced cystitis in the rat. Am J Physiol Regul Integr Comp Physiol 2003; 284: R574-85.
29. Abrahamsson K, Olsson I, Sillen U,. Urodynamic findings in children with myelomeningocele after untethering of the spinal cord. J Urol 2007; 177: 331-4 discussion 334.
30. Fry CH, Meng E, Young JS,. The physiological function of lower urinary tract smooth muscle. Auton Neurosci 2010; 154: 3-13.
31. Fowler CJ, Griffiths D, de Groat WC,. The neural control of micturition. Nat Rev Neurosci 2008; 9: 453-66.
32. Andersson KE,. Mechanisms of Disease: Central nervous system involvement in overactive bladder syndrome. Nat Clin Pract Urol 2004; 1: 103-8.
33. Dasgupta J, Tincello DG,. Interstitial cystitis/bladder pain syndrome: An update. Maturitas 2009; 64: 212-7.
34. Patel BN, Evans RJ,. Overactive bladder and pain: Management strategies. Curr Urol Rep 2010; 11: 379-84.
35. Miki T, Matsunami M, Nakamura S, et al. ONO-8130, a selective prostanoid EP1 receptor antagonist, relieves bladder pain in mice with cyclophosphamide- induced cystitis. Pain 2011. 152: 1373-1381.
36. Olivar T, Laird JM,. Cyclophosphamide cystitis in mice: Behavioural characterisation and correlation with bladder inflammation. Eur J Pain 1999; 3: 141-9.
37. Wang ZY, Wang P, Merriam FV, et al. Lack of TRPV1 inhibits cystitis-induced increased mechanical sensitivity in mice. Pain 2008; 139: 158-67.
38. OchodnickÁ P, Cruz CD, Yoshimura N, et al. Nerve growth factor in bladder dysfunction: Contributing factor, biomarker, and therapeutic target. Neurourol Urodyn 2011. DOI: 10.1002/nau.21022. [Epub ahead of print].